At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 24 enrolled
Drug / intervention
Patisirandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) With Disease Progression Post-Orthotopic Liver Transplant
In Brief
A Phase 3 clinical trial evaluating Patisiran for Amyloidosis, Familial and Transthyretin Amyloidosis. Completed, enrolled 24 participants across 9 sites in 7 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of patisiran in participants with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with disease progression after liver transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyloidosis, Familial, Transthyretin Amyloidosis
CountriesFrance, Germany, Italy, Portugal, Spain, Sweden, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMar 2019
Enrollment StartMar 2019
Primary CompletionOct 2020
Study CompletionOct 2020
TodayJul 2026
First PostedMar 5, 2019
Enrollment StartMar 27, 2019
Primary CompletionOct 6, 2020
Study CompletionOct 20, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.3 years ago
Interventions
Patisirandrug
Patisiran was administered via IV infusion.